Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
This settlement is closed!
Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!
Bristol-Myers Squibb has agreed to a $10 million HIV drugs class action lawsuit settlement to resolve antitrust claims involving Evotaz and Atripla.
The partial settlement benefits patients, purchasers, and all other entities who paid for brand-name or generic Atripla or Evotaz between May 14, 2015, and Oct. 13, 2021.
Bristol-Myers Squibb is one of numerous companies that manufacture combination HIV drugs. The company specifically manufactures Evotaz, a combination of atazanavir and cobicistat.
Bristol-Myers Squibb, Gilead Sciences, Janssen, and other companies were accused of valuing profits over patients by inflating the cost of their combination HIV drugs through anti-competitive agreements. These agreements allegedly suppressed or delayed the availability of generic alternatives.
As a result, patients and insurers are allegedly forced to pay inflated prices for life-saving medications.
Bristol-Myers Squibb hasn’t admitted any wrongdoing but agreed to settle the claims surrounding Evotaz and Atripla with a $10 million class action settlement.
Under the terms of the Bristol-Myers Squibb HIV drugs class action lawsuit settlement, $2.5 million will be distributed amongst members of the Atripla and Evotaz Classes. Exact payment amounts will vary depending on the number of claims filed.
Of the $10 million settlement, $5 million will be set aside for the resolution of future claims in the HIV drugs class action settlement. If there are no further settlements, the remaining funds from Bristol-Myers Squibb will be distributed amongst Evotaz and Atripla claimants.
In addition to providing cash benefits, the settlement with Bristol-Myers Squibb waives a provision in the company’s Evotaz agreement with Gilead. As a result of this waiver, Gilead may choose to change some of its combination HIV drug marketing.
This $10 million settlement doesn’t completely resolve the claims against the pharmaceutical giants. The partial settlement deal only resolves claims surrounding brand-name or generic Atripla or Evotaz.Â
Claims remain surrounding other companies and their handling of Biktarvy, Complera, Descovy, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread.
Other settlements surrounding other HIV drugs may occur in the future. Subscribe to Top Class Actions’ weekly newsletter to stay updated on new open settlements.
The deadline for exclusion and objection is March 15, 2022.Â
The final approval hearing in the Bristol-Myers Squibb HIV drugs class action lawsuit settlement is scheduled for April 28, 2022.
In order to benefit from the settlement, purchasers of HIV drugs must submit a valid claim form within 60 days of the final approval date.Â
Based on the scheduled final approval hearing date, the estimated claim deadline is June 27, 2022. However, the actual claim deadline could be earlier or later, depending on the actual date of final approval.
Who’s Eligible
Settlement benefits patients, purchasers, and all other entities who paid for brand-name or generic Atripla or Evotaz between May 14, 2015, and Oct. 13, 2021.
Potential Award
Varies.
Proof of Purchase
Settlement Administrator may ask for additional proof supporting your claim.
1. Itemized receipts that show payment(s) for the subject drugs; or
2. An EOB (explanation of benefits) from your insurer that shows you paid for the subject drugs; or
3. Records from your pharmacy showing that you paid for the subject drugs; or
4. Copies of records showing prescriptions written for the subject drugs.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
06/27/2022
Case Name
Staley, et al. v. Gilead Sciences, Inc., et al., Case No. 3:19-cv-02573-EMC in the U.S. District Court for the Northern District of California
Final Hearing
04/28/2022
Settlement Website
Claims Administrator
Staley, et al. v. Gilead Sciences, Inc., et al.
P.O. Box 173017
Milwaukee, WI 53217
info@HIVDrugSettlement.com
877-999-2491
Class Counsel
Steve W. Berman
HAGENS BERMAN SOBOL SHAPIRO LLP
Steve Shadowen
HILLIARD & SHADOWEN LLP
Daralyn J. Durie
DURIE TANGRI LLP
Defense Counsel
Aileen M. FairSenior
Corporate Counsel
Litigation & Government Investigations
BRISTOL-MYERS SQUIBB COMPANY
Daniel B. Asimow
Laura S. Shores
James L. Cooper
Anne P. Davis
ARNOLD & PORTER KAYE SCHOLER LLP
Read About More Class Action Lawsuits & Class Action Settlements:
- Neuriva Supplements False Ad $8M Class Action Settlement
- CannTrust $83M Securities Class Action Settlement
- Health Insurance Innovations $27.5M Class Action Settlement
- Molekule Air Purifiers False Ad $1.3M Class Action Settlement
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
2 thoughts onEvotaz, Atripla HIV drugs antitrust $10M class action settlement
Denial letter today
Atripla is incredibly toxic and Gilead absolutely kept a safer drug off the market to keep making money on their first brand. SIGN. ME. UP.